Company Analysis
Sign in

OKYO Pharma Limited (OKYO)

Nasdaq: OKYO · Biological Products, (No Diagnostic Substances) · London, GB · filing with the SEC since 2021
Full chart Alerts Compare
Grade4.7
◀ Past 5.3● Present 3.4▶ Future 5.4
8 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts.

The Form 20-F filed Jul 20, 2026 for the period ended Mar 31, 2026 is not in EDGAR's company facts yet; its figures here are that filing's own, read from the SEC's financial statement data sets.

Income statement, by fiscal year, newest first
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingMar 31, 2026Mar 31, 2025Mar 31, 2024Mar 31, 2023Mar 31, 2022Mar 31, 2021Mar 31, 2020
Report filedJul 20, 2026Jul 18, 2025Aug 13, 2024Aug 15, 2023Aug 15, 2022··
Research and development1,809,0442,254,2448,243,5716,337,6981,609,558r348,347r518,098
Total operating expenses6,690,5094,837,6537,506,1616,849,5024,608,008r3,017,859r1,016,548
Finance costs·878,1741,053,31396,687·1,1231,158
Finance income·5,473····48,125
Net finance income (costs)-442,117-878,174-1,053,313····
Income before income taxes-8,941,670-7,970,071-16,803,045-13,283,887-6,217,566-3,378,501-1,620,347
Income tax expense·3,263,779-22,41612,202786,52124,99476,289
Net income-8,949,657-4,706,292-16,825,461-13,271,685-5,431,045-3,353,507-1,544,059
Net income to ordinary shareholders·-7,970,071-16,825,461-13,271,685-5,431,045r-3,353,507-1,544,059
Earnings per share, basic-0.24-0.12r-0.57-0.61-0.36-0.32·
Earnings per share, diluted-0.24-0.12r-0.57-0.61-0.36-0.32·
Weighted average shares, basic····979,212,888672,767,629595,474,039
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells nextifrs-full:ResearchAndDevelopmentExpense
Total operating expenses the running costs togetherifrs-full:OperatingExpense
Finance costs what its borrowing costifrs-full:FinanceCosts
Finance income what its cash and investments earnedifrs-full:FinanceIncome
Net finance income (costs) interest earned less interest paid, outside the businessifrs-full:FinanceIncomeCost
Income before income taxes profit before taxifrs-full:ProfitLossBeforeTax
Income tax expense tax charged on the period's profitifrs-full:IncomeTaxExpenseContinuingOperations
Net income the whole group's profit, minority holders' share includedifrs-full:ProfitLoss
Net income to ordinary shareholders what is left for common shareholdersifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
Earnings per share, basic net income per share outstandingifrs-full:BasicEarningsLossPerShare
Earnings per share, diluted net income per share, counting every share that could be issuedifrs-full:DilutedEarningsLossPerShare
Weighted average shares, basic the average count of shares outstandingifrs-full:WeightedAverageShares
SI Assistanton OKYO · research, not advice